What changed: Perivascular epithelioid cell tumour (PEComa)
Every dated change on the records linked to Perivascular epithelioid cell tumour (PEComa), newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
Approval1Trial result1Milestone4This record1
September 2026 · 1
2021 · 3
- 2021ApprovalSirolimus protein-bound particlesSirolimus protein-bound particles approved in US
Locally advanced unresectable or metastatic malignant PEComa
- 2021Trial resultAMPECTAMPECT reported
Objective response 39% (independent review), durable, enriched in TSC2-mutant tumours; FDA approval November 2021.
- 2021MilestoneAMPECTAMPECT: nab-sirolimus approved for advanced malignant PEComa
A milestone in how this cancer is treated.